Palivizumab - Biologic Drug Details

Summary for palivizumab

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for palivizumab

Recent Clinical Trials for palivizumab

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
AstraZeneca	NA
Anabio R&D	NA
National Children's Hospital, Vietnam	NA

See all palivizumab clinical trials

Pharmacology for palivizumab

Mechanism of Action	Fusion Protein Inhibitors
Established Pharmacologic Class	Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody
Chemical Structure	Antibodies, Monoclonal

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for palivizumab Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for palivizumab Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for palivizumab Derived from Patent Text Search

No patents found based on company disclosures

Palivizumab Market Analysis and Financial Projection

Last updated: February 14, 2026

What Are the Market Dynamics for Palivizumab?

Palivizumab, marketed under the brand Synagis, is a monoclonal antibody used as a prophylactic agent against respiratory syncytial virus (RSV). Its market depends on several factors:

Key Market Drivers

• Target Population Size: Infants and young children at high risk, such as preterm infants (less than 35 weeks gestation), those with congenital heart disease, or chronic lung disease.
• RSV Incidence: Seasonal outbreaks occur predominantly in winter months, with regional variability influencing vaccine demand.
• Approval and Indications: Regulatory approvals from bodies like the FDA and EMA restrict usage to high-risk groups, shaping the market size.
• Healthcare Guidelines: Recommendations by organizations such as the American Academy of Pediatrics (AAP) and European counterparts specify prophylaxis criteria, influencing prescribing practices.

Market Limiters

• High Cost: Approximate annual treatment costs per patient are $4,000–$6,000, limiting accessibility and influencing payer policies.
• Administration Constraints: Requires intramuscular injections monthly during RSV season, often over five months in high-incidence regions.
• Competition and Alternatives: Vaccines in development aim to replace or supplement palivizumab, with some showing promise.
• Pricing and Reimbursement Policies: Variability across countries affects uptake effectively; reimbursement limits in some jurisdictions reduce market penetration.

Competitive Landscape

• Existing Drugs: Palivizumab remains the primary prophylactic monoclonal antibody.
• Emerging Therapies: Nirsevimab, a next-generation monoclonal antibody, seeks approval for broader use, potentially challenging palivizumab's market share.
• Vaccine Development: Several RSV vaccine candidates in late-stage clinical trials target broader populations, which may dilute the market for palivizumab in the future.

How Is the Financial Trajectory of Palivizumab Evolving?

Revenue Trends

• Sales Data: In 2022, global sales of palivizumab reached approximately $1.2 billion, with North America accounting for the majority.
• Market Growth Rate: Estimated compound annual growth rate (CAGR) from 2018–2022 stood at around 2.5%, driven by increasing awareness and vaccination guidelines.
• Regional Variations: The US and Europe contribute 80% of sales; emerging markets have lower adoption due to cost and regulatory barriers.

Cost and Pricing Dynamics

• Pricing Trends: List prices tend to increase annually, around 3–5%, with discounts and rebates varying by payer negotiations.
• Reimbursement Policies: Generally cover prophylaxis for eligible high-risk infants; however, coverage policies can limit access, affecting revenue stability.

Impact of Competition

• Nirsevimab received FDA breakthrough therapy designation in 2022 and is projected to enter the market by 2025. Its broader indication scope could disrupt palivizumab's sales.
• Potential Biosimilars: No biosimilar competitors exist as of 2023, owing to patent protections and the complexity of manufacturing monoclonal antibodies.

Forecasts

• Market Size Projection: Expected to reach $1.5 billion by 2027, with a modest CAGR of 2-3%, assuming no significant entry of new prophylactic agents.
• Impact of Emerging Therapies: Introduction of vaccines and longer-acting monoclonal antibodies is likely to slow growth or lead to market decline post-2025.

What Are the Market Policies and Regulatory Considerations?

• Regulatory Approvals: Approved for prophylaxis in high-risk infants in over 80 countries, with some variation in indications and dosing schedules.
• Pricing and Reimbursement: Strict in developed markets; some emerging markets face access limitations due to cost. Policy changes can influence market size.
• Clinical Guidelines: Set by pediatric and infectious disease societies form a basis for reimbursement and prescribing patterns, directly impacting sales.

Final Insights

Palivizumab’s market remains stable but limited by cost, administration logistics, and regional policy differences. Its financial trajectory shows slow growth, with potential decline due to upcoming competition from longer-lasting monoclonal antibodies and vaccines.

Key Takeaways

• The global palivizumab market was approximately $1.2 billion in 2022, with North America leading.
• Growth is constrained by high costs, limited eligible populations, and regulatory/reimbursement hurdles.
• The advent of nirsevimab and RSV vaccines pose significant competitive threats over the next three to five years.
• Regional variations in reimbursement and guidelines affect market penetration.
• The market is expected to grow slowly, reaching around $1.5 billion by 2027, before facing potential decline due to newer prophylactics.

FAQs

1. What are the main factors influencing palivizumab’s market size?
The size depends on the incidence of high-risk RSV cases, regulatory approvals, healthcare guidelines, and reimbursement policies.

2. How does the upcoming nirsevimab impact palivizumab?
Nirsevimab offers broader, longer-lasting protection, potentially replacing palivizumab in some markets, especially if approved for wider populations.

3. What are the barriers to market growth for palivizumab?
High treatment costs, limited eligible populations, administration requirements, and evolving regulatory landscapes restrict expansion.

4. Which regions generate the bulk of palivizumab sales?
North America accounts for about 70–75% of sales; Europe contributes roughly 10–15%, with emerging markets playing a minimal role currently.

5. How might policy changes alter the market trajectory?
More restrictive reimbursement or updated clinical guidelines could reduce the number of covered patients, shrinking the market. Conversely, expanded guidelines could boost sales.

---

Citations

[1] IQVIA. “Global Respiratory Syncytial Virus (RSV) Market 2022.”
[2] CDC, “Respiratory Syncytial Virus Infection (RSV),” 2022.
[3] European Medicines Agency (EMA). “Synagis (Palivizumab) approval details,” 2022.
[4] FDA. “Nirsevimab Breakthrough Therapy Designation,” 2022.
[5] MarketWatch. “Palivizumab market analysis and forecasts,” 2023.